Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure (COPE)
Patient Workbook
Published on 20. November 2014
Book
Paperback/Softback
192 pages
978-0-19-933451-3 (ISBN)
Description
Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure (COPE) is a cognitive-behavioral psychotherapy program designed for patients who have posttraumatic stress disorder (PTSD) and a co-occurring alcohol or drug use disorder. COPE represents an integration of two evidence-based treatments: Prolonged Exposure (PE) therapy for PTSD and Relapse Prevention for substance use disorders.
COPE is an integrated treatment, meaning that both the PTSD and substance use disorder are addressed concurrently in therapy by the same clinician, and patients can experience substantial reductions in both PTSD symptoms and substance use severity. Patients use the COPE Patient Workbook while their clinician uses the Therapist Guide to deliver treatment. The program is comprised of 12 individual, 60 to 90 minute therapy sessions. The program includes several components: information about how PTSD symptoms and substance use interact with one another; information about the most common reactions to trauma; techniques to help the patient manage cravings and thoughts about using alcohol or drugs; coping skills to help the patient prevent relapse to substances; a breathing retraining relaxation exercise; and in vivo (real life) and imaginal exposures to target the patient's PTSD symptoms.
COPE is an integrated treatment, meaning that both the PTSD and substance use disorder are addressed concurrently in therapy by the same clinician, and patients can experience substantial reductions in both PTSD symptoms and substance use severity. Patients use the COPE Patient Workbook while their clinician uses the Therapist Guide to deliver treatment. The program is comprised of 12 individual, 60 to 90 minute therapy sessions. The program includes several components: information about how PTSD symptoms and substance use interact with one another; information about the most common reactions to trauma; techniques to help the patient manage cravings and thoughts about using alcohol or drugs; coping skills to help the patient prevent relapse to substances; a breathing retraining relaxation exercise; and in vivo (real life) and imaginal exposures to target the patient's PTSD symptoms.
Reviews / Votes
Co-morbidity of PTSD and substance use disorders is as challenging as it is common in clinical practice. COPE offers the first integrated approach to treatment of these patients that has a solid foundation in evidence-based techniques and applies insights from basic neuroscience. Our experience with COPE for PTSD patients with alcohol addiction has been truly amazing. * Markus Heilig, MD PhD, Chief, Lab of Clinical and Translational Studies, NIAAA * COPE is a much-needed integrated treatment for substance use and posttraumatic stress disorders. This excellent therapist manual, and its accompanying patient workbook, will provide important guidance for clinicians in delivering COPE, thereby expanding the possibility of providing high-quality integrated care for individuals suffering from both of these illnesses. * Shelly F. Greenfield, MD, MPH, Chief Academic Officer, Chief, Division of Women's Mental Health, and Director of Clinical and Health Services Research and Education, Division of Alcohol and Drug Abuse, McLean Hospital, and Professor of Psychiatry, Harvard Medical School * COPE is a long awaited and much needed treatment manual, developed by an outstanding group of clinicians and researchers. COPE will allow exposure therapy, a highly effective treatment for PTSD, to be more readily available to patients who also have a substance use disorder. I recommend this book to anyone who treats patients who have both PTSD and a substance use disorder. * Sonya B. Norman, PhD, Associate Professor, Department of Psychiatry, University of California, San Diego * This pair of books brings science-based treatment techniques and skills to a population of clients and therapists in urgent need. Based on years of careful and systematic development, these books provide critical training in how to deliver prolonged exposure therapy techniques in those with substance addictions. They are a groundbreaking addition to any trauma and addiction therapist's treatment collection. * Denise Hien, PhD, ABPP, Professor of Clinical Psychology, City College, Graduate Center of the City University of New York * Clients will appreciate the user-friendly forms and worksheets to supplement their treatment with a qualified mental health professional. The workbook is also designed for clients who are motivated to work on their own. * Doody's Notes *More details
Series
Language
English
Place of publication
New York
United States
Target group
Professional and scholarly
Dimensions
Height: 280 mm
Width: 216 mm
Thickness: 11 mm
Weight
494 gr
ISBN-13
978-0-19-933451-3 (9780199334513)
Copyright in bibliographic data and cover images is held by Nielsen Book Services Limited or by the publishers or by their respective licensors: all rights reserved.
Schweitzer Classification
Other editions
Additional editions
Sudie E. Back | Edna B. Foa | Therese K. Killeen
Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure (COPE)
Patient Workbook
E-Book
09/2014
1st Edition
OUP eBook
€36.99
Available for download
Persons
Sudie E. Back, Ph.D., is a Professor in the Department of Psychiatry and Behavioral Sciences at the Medical University of South Carolina, and a Staff Psychologist at the Ralph H. Johnson Veterans Affairs (VA) Medical Center in Charleston, SC. She is Director of the NIDA-sponsored Drug Abuse Research Training (DART) residency and summer research programs at the Medical University of South Carolina.
Edna B. Foa, Ph.D., is a Professor of Clinical Psychology in Psychiatry at the University of Pennsylvania, and Director of the Center for the Treatment and Study of Anxiety. Dr. Foa devoted her academic career to study the psychopathology and treatment of anxiety disorders, primarily obsessive-compulsive disorder (OCD) and post-traumatic stress disorder (PTSD).
Therese K. Killeen, Ph.D., APRN, is an Associate Professor in the Department of Psychiatry and Behavioral Sciences at the Medical University of South Carolina. Dr. Killeen has over 20 years of experience working with adult and adolescent patients with comorbid PTSD and substance use disorders.
Katherine L. Mills, Ph.D., is an Associate Professor at the National Drug and Alcohol Research Centre, University of New South Wales. Dr. Mills is also Director of Treatment Research for the National Health and Medical Research Council (NHMRC) Centre of Research Excellence in Mental Health and Substance Use in Australia.
Maree Teesson, Ph.D., is a National Health and Medical Research Council (NHMRC) Senior Research Fellow at the National Drug and Alcohol Research Centre, University of New South Wales, and Director of the NHMRC Centre of Research Excellence in Mental Health and Substance Use in Australia.
Bonnie Dansky Cotton, Ph.D., is a senior manager at Microsoft Corporation. She received her PhD in Clinical Psychology from Duke University and completed her internship at the Medical University of South Carolina. Prior to her career at Microsoft, Dr. Cotton was an Assistant Professor in the Department of Psychiatry and Behavioral Sciences at the Medical University of South Carolina.
Kathleen M. Carroll, Ph.D., is the Albert E. Kent Professor of Psychiatry at Yale University School of Medicine. She is an internationally renowned researcher on the development of behavioral therapies for substance use disorders. Dr. Carroll is Principal Investigator of the Center for Psychotherapy Development at Yale and Co-Principal Investigator of the New England Consortium of NIDA's Clinical Trials Network.
Kathleen T. Brady, MD, Ph.D., is a Distinguished University Professor and Associate Provost for Clinical and Translational Science at the Medical University of South Carolina. Dr. Brady is Director of the Women's Research Center, Director of the MUSC Clinical and Translational Research Center (CTSA), and Director of the Southern Consortium of NIDA's Clinical Trials Network.
Edna B. Foa, Ph.D., is a Professor of Clinical Psychology in Psychiatry at the University of Pennsylvania, and Director of the Center for the Treatment and Study of Anxiety. Dr. Foa devoted her academic career to study the psychopathology and treatment of anxiety disorders, primarily obsessive-compulsive disorder (OCD) and post-traumatic stress disorder (PTSD).
Therese K. Killeen, Ph.D., APRN, is an Associate Professor in the Department of Psychiatry and Behavioral Sciences at the Medical University of South Carolina. Dr. Killeen has over 20 years of experience working with adult and adolescent patients with comorbid PTSD and substance use disorders.
Katherine L. Mills, Ph.D., is an Associate Professor at the National Drug and Alcohol Research Centre, University of New South Wales. Dr. Mills is also Director of Treatment Research for the National Health and Medical Research Council (NHMRC) Centre of Research Excellence in Mental Health and Substance Use in Australia.
Maree Teesson, Ph.D., is a National Health and Medical Research Council (NHMRC) Senior Research Fellow at the National Drug and Alcohol Research Centre, University of New South Wales, and Director of the NHMRC Centre of Research Excellence in Mental Health and Substance Use in Australia.
Bonnie Dansky Cotton, Ph.D., is a senior manager at Microsoft Corporation. She received her PhD in Clinical Psychology from Duke University and completed her internship at the Medical University of South Carolina. Prior to her career at Microsoft, Dr. Cotton was an Assistant Professor in the Department of Psychiatry and Behavioral Sciences at the Medical University of South Carolina.
Kathleen M. Carroll, Ph.D., is the Albert E. Kent Professor of Psychiatry at Yale University School of Medicine. She is an internationally renowned researcher on the development of behavioral therapies for substance use disorders. Dr. Carroll is Principal Investigator of the Center for Psychotherapy Development at Yale and Co-Principal Investigator of the New England Consortium of NIDA's Clinical Trials Network.
Kathleen T. Brady, MD, Ph.D., is a Distinguished University Professor and Associate Provost for Clinical and Translational Science at the Medical University of South Carolina. Dr. Brady is Director of the Women's Research Center, Director of the MUSC Clinical and Translational Research Center (CTSA), and Director of the Southern Consortium of NIDA's Clinical Trials Network.
Author
ProfessorProfessor, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina
Professor of Clinical Psychology in PsychiatryProfessor of Clinical Psychology in Psychiatry, University of Pennsylvania
Associate ProfessorAssociate Professor, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina
Associate ProfessorAssociate Professor, National Drug and Alcohol Research Centre, University of New South Wales
NHMRC Senior Research FellowNHMRC Senior Research Fellow, National Drug and Alcohol Research Centre, University of New South Wales
Senior ManagerSenior Manager, Microsoft
Albert E. Kent Professor of PsychiatryAlbert E. Kent Professor of Psychiatry, Yale University School of Medicine
Distinguished University Professor and Associate Provost for Clinical and Translational ScienceDistinguished University Professor and Associate Provost for Clinical and Translational Science, Medical University of South Carolina
Content
Chapter 1: Introduction ; Chapter 2: Is This Program Right for You? ; Chapter 3: Session 1 ; Chapter 4: Session 2 ; Chapter 5: Session 3 ; Chapter 6: Session 4 ; Chapter 7: Session 5 ; Chapter 8: Session 6 ; Chapter 9: Session 7 ; Chapter 10: Session 8 ; Chapter 11: Session 9 ; Chapter 12: Session 10 ; Chapter 13: Session 11 ; Chapter 14: Session 12 ; Appendices